インフルエンザ治療の世界市場レポート 2025年

インフルエンザ治療の市場規模は、今後数年間で安定した成長が見込まれます。2029年には年間平均成長率（CAGR）4.3%で81億6,000万米ドルに成長します。予測期間の成長は、新しい抗ウイルス薬や治療法の導入、ワクチン接種プログラムの拡大、ヘルスケアインフラの継続的な拡大と改善、高齢者人口の増加、新しい治療法の開発などに起因すると考えられます。予測期間における主な動向としては、万能ワクチンの開発への進展、ワクチン送達システムの革新、AIとビッグデータの統合、個別化医療の進歩、製薬企業間の協力関係の強化などが挙げられます。

伝染性呼吸器疾患の罹患率の上昇は、インフルエンザ治療市場を前進させると予測されます。伝染性呼吸器疾患には、インフルエンザ、麻疹、呼吸器合胞体ウイルス（RSV）感染症などの感染症が含まれ、感染者またはその体液、汚染された表面、物との接触によって広がります。伝染性呼吸器疾患の増加に拍車をかけている要因としては、人口密度の増加、不十分なヘルスケアインフラ、抗生物質の誤用、海外渡航の促進などが挙げられます。インフルエンザ治療では、インフルエンザ、COVID-19、その他の呼吸器系ウイルスなど、さまざまな伝染性の呼吸器疾患を管理するために、抗ウイルス薬や予防接種が使用されています。例えば、米国を拠点とする国立公衆衛生機関である疾病対策予防センター（CDC）によると、2023年9月、RSV（呼吸器シンシチアルウイルス）に関連する入院率は、2023年8月5日に終わる週には10万人当たり2人であったのが、2023年8月19日に終わる週には10万人当たり7人に増加しました。したがって、伝染性の呼吸器疾患の有病率の増加がインフルエンザ治療市場の成長を促進しています。

インフルエンザ治療市場の有力企業は、患者のアドヒアランスを高め、治療成果を改善し、より大きな市場シェアを確保することを目的として、インフルエンザ治療用の単回投与経口薬などの革新的なソリューションを導入することにより、製品の幅を広げることに注力しています。単回経口薬とは、1回の経口投与でインフルエンザに対応できるように製剤化された薬剤で、治療レジメンを簡素化することができます。例えば、2022年8月、米国のバイオテクノロジー企業であるジェネンテック社は、Xofluza（Baloxavir Marboxil）の米国食品医薬品局（FDA）承認を明らかにしました。Xofluzaは、48時間以内に症状を呈した5歳から12歳未満の小児およびその他の呼吸器系ウイルスの合併症のない急性インフルエンザを管理するための便利で効果的なソリューションを提供する、唯一の単回投与経口薬です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界インフルエンザ治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のインフルエンザ治療市場：成長率分析
• 世界のインフルエンザ治療市場の実績：規模と成長, 2019-2024
• 世界のインフルエンザ治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界インフルエンザ治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のインフルエンザ治療市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペラミビル
• ザナミビル
• リン酸オセルタミビル
• バロキサビルマルボキシル
• その他の製品
• 世界のインフルエンザ治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• その他の投与経路
• 世界のインフルエンザ治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• 病院薬局
• その他の流通チャネル
• 世界のインフルエンザ治療市場ペラミビルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内ペラミビル
• ペラミビル注射剤
• 世界のインフルエンザ治療市場ザナミビルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 吸入ザナミビル
• ザナミビル・ディスクヘラー
• 世界のインフルエンザ治療市場リン酸オセルタミビルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オセルタミビルカプセル
• オセルタミビル経口懸濁液
• 世界のインフルエンザ治療市場バロキサビルマルボキシルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バロキサビル錠
• バロキサビル経口懸濁液顆粒
• 世界のインフルエンザ治療市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リマンタジン
• アマンタジン

第7章 地域別・国別分析

• 世界のインフルエンザ治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のインフルエンザ治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インフルエンザ治療市場：競合情勢
• インフルエンザ治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Fujifilm Holdings Corporation
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals Inc.
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company Limited.
• Chugai Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Limited
• Cipla Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インフルエンザ治療市場2029：新たな機会を提供する国
• インフルエンザ治療市場2029：新たな機会を提供するセグメント
• インフルエンザ治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Influenza treatment involves medical measures intended to manage and relieve symptoms, shorten the duration of illness, and prevent complications linked to influenza virus infections. It includes antiviral drugs and supportive care aimed at alleviating flu symptoms, shortening the illness duration, and averting severe complications.

The primary products employed for treating influenza include peramivir, zanamivir, oseltamivir phosphate, baloxavir marboxil, and others. Peramivir is an antiviral drug utilized for influenza treatment. These medications can be administered via various routes, including orally and others, and are available through different distribution channels, such as retail pharmacies, hospital pharmacies, and others.

The influenza treatment market research report is one of a series of new reports from The Business Research Company that provides influenza treatment market statistics, including influenza treatment industry global market size, regional shares, competitors with a influenza treatment market share, detailed influenza treatment market segments, market trends and opportunities, and any further data you may need to thrive in the influenza treatment industry. This influenza treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza treatment market size has grown steadily in recent years. It will grow from $6.6 billion in 2024 to $6.9 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to a growth in number of annual influenza cases, increased government funding for influenza research and preparedness programs, public awareness campaigns promoting vaccination, the establishment of global influenza surveillance systems, and growth in healthcare facilities.

The influenza treatment market size is expected to see steady growth in the next few years. It will grow to $8.16 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to the introduction of new antiviral drugs and treatment modalities, expanding vaccination programs, continued expansion and improvement of healthcare infrastructure, increasing elderly population, and development of new treatments. Major trends in the forecast period include progress toward developing universal vaccines, innovations in vaccine delivery systems, integration of AI and big data, advances in personalized medicine, and increased collaborations between pharmaceutical companies.

The rising incidence of contagious respiratory illnesses is anticipated to drive the influenza treatment market forward. Contagious respiratory illnesses encompass infectious diseases such as influenza, measles, or respiratory syncytial virus (RSV) infections, which spread through contact with infected individuals or their bodily fluids, contaminated surfaces, or objects. Factors fueling the increase in contagious respiratory illnesses include higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and facilitated international travel. Influenza treatment involves the use of antiviral drugs and vaccinations to manage various contagious respiratory illnesses such as flu, COVID-19, and other respiratory viruses. For example, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the hospitalization rate associated with RSV (Respiratory Syncytial Virus) rose from 2 hospitalizations per 100,000 individuals during the week ending August 5, 2023, to 7 hospitalizations per 100,000 individuals by the week ending on August 19, 2023. Hence, the increased prevalence of contagious respiratory illnesses is propelling the growth of the influenza treatment market.

Prominent companies in the influenza treatment market are concentrating on broadening their product range by introducing innovative solutions, such as single-dose oral medication for influenza treatment, with the aim of enhancing patient adherence, improving treatment outcomes, and securing a larger market share. A single-dose oral medication is a drug formulated to address influenza (flu) with just one oral dose, simplifying the treatment regimen. For example, in August 2022, Genentech Inc., a US-based biotechnology company, revealed the U.S. Food and Drug Administration (FDA) approval for Xofluza (Baloxavir Marboxil). Xofluza stands as the premier and sole single-dose oral medication, providing a convenient and effective solution for managing acute uncomplicated influenza in children aged five to less than 12 years who have exhibited symptoms for no more than 48 hours, as well as other respiratory viruses.

In June 2022, Pfizer Inc., a pharmaceutical company headquartered in the United States, purchased ReViral for an undisclosed sum. This acquisition is aimed at broadening Pfizer's product portfolio by incorporating one of the therapeutic candidates, Sisunatovir, which is an orally administered inhibitor designed to specifically impede the fusion of the respiratory syncytial virus (RSV) with the host cell. ReViral is a biotechnology company based in the United Kingdom, known for its development and provision of innovative therapies for viral diseases.

Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd, Dr. Reddy's Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

North America was the largest region in the influenza treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the influenza treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The influenza treatment market consists of sales of ibuprofen, dextromethorphan, acetaminophen, and nasal sprays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Influenza Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on influenza treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for influenza treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The influenza treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Peramivir; Zanamivir; Oseltamivir Phosphate; Baloxavir Marboxil; Other Products
• 2) By Route Of Administration: Oral; Other Routes Of Administration
• 3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Other Distribution Channels
• Subsegments:
• 1) By Peramivir: Intravenous Peramivir; Peramivir Injection
• 2) By Zanamivir: Inhaled Zanamivir; Zanamivir Diskhaler
• 3) By Oseltamivir Phosphate: Oseltamivir Capsules; Oseltamivir Oral Suspension
• 4) By Baloxavir Marboxil: Baloxavir Tablets; Baloxavir Granules For Oral Suspension
• 5) Other Products: Rimantadine; Amantadine
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Influenza Treatment Market Characteristics

3. Influenza Treatment Market Trends And Strategies

4. Influenza Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Influenza Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Influenza Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Influenza Treatment Market Growth Rate Analysis
• 5.4. Global Influenza Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Influenza Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Influenza Treatment Total Addressable Market (TAM)

6. Influenza Treatment Market Segmentation

• 6.1. Global Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peramivir
• Zanamivir
• Oseltamivir Phosphate
• Baloxavir Marboxil
• Other Products
• 6.2. Global Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Other Routes Of Administration
• 6.3. Global Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacy
• Hospital Pharmacy
• Other Distribution Channels
• 6.4. Global Influenza Treatment Market, Sub-Segmentation Of Peramivir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Peramivir
• Peramivir Injection
• 6.5. Global Influenza Treatment Market, Sub-Segmentation Of Zanamivir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhaled Zanamivir
• Zanamivir Diskhaler
• 6.6. Global Influenza Treatment Market, Sub-Segmentation Of Oseltamivir Phosphate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oseltamivir Capsules
• Oseltamivir Oral Suspension
• 6.7. Global Influenza Treatment Market, Sub-Segmentation Of Baloxavir Marboxil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Baloxavir Tablets
• Baloxavir Granules For Oral Suspension
• 6.8. Global Influenza Treatment Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rimantadine
• Amantadine

7. Influenza Treatment Market Regional And Country Analysis

• 7.1. Global Influenza Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Influenza Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Influenza Treatment Market

• 8.1. Asia-Pacific Influenza Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Influenza Treatment Market

• 9.1. China Influenza Treatment Market Overview
• 9.2. China Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Influenza Treatment Market

• 10.1. India Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Influenza Treatment Market

• 11.1. Japan Influenza Treatment Market Overview
• 11.2. Japan Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Influenza Treatment Market

• 12.1. Australia Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Influenza Treatment Market

• 13.1. Indonesia Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Influenza Treatment Market

• 14.1. South Korea Influenza Treatment Market Overview
• 14.2. South Korea Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Influenza Treatment Market

• 15.1. Western Europe Influenza Treatment Market Overview
• 15.2. Western Europe Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Influenza Treatment Market

• 16.1. UK Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Influenza Treatment Market

• 17.1. Germany Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Influenza Treatment Market

• 18.1. France Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Influenza Treatment Market

• 19.1. Italy Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Influenza Treatment Market

• 20.1. Spain Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Influenza Treatment Market

• 21.1. Eastern Europe Influenza Treatment Market Overview
• 21.2. Eastern Europe Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Influenza Treatment Market

• 22.1. Russia Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Influenza Treatment Market

• 23.1. North America Influenza Treatment Market Overview
• 23.2. North America Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Influenza Treatment Market

• 24.1. USA Influenza Treatment Market Overview
• 24.2. USA Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Influenza Treatment Market

• 25.1. Canada Influenza Treatment Market Overview
• 25.2. Canada Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Influenza Treatment Market

• 26.1. South America Influenza Treatment Market Overview
• 26.2. South America Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Influenza Treatment Market

• 27.1. Brazil Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Influenza Treatment Market

• 28.1. Middle East Influenza Treatment Market Overview
• 28.2. Middle East Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Influenza Treatment Market

• 29.1. Africa Influenza Treatment Market Overview
• 29.2. Africa Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Influenza Treatment Market Competitive Landscape And Company Profiles

• 30.1. Influenza Treatment Market Competitive Landscape
• 30.2. Influenza Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Influenza Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline Plc
• 31.4. Takeda Pharmaceutical Company
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Gilead Sciences Inc.
• 31.7. Fujifilm Holdings Corporation
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Janssen Pharmaceuticals Inc.
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Daiichi Sankyo Company Limited.
• 31.13. Chugai Pharmaceutical Co. Ltd.
• 31.14. Sun Pharmaceutical Industries Limited
• 31.15. Cipla Ltd

32. Global Influenza Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Influenza Treatment Market

34. Recent Developments In The Influenza Treatment Market

35. Influenza Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Influenza Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Influenza Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Influenza Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer